Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $95,572.40 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 154 shares of the business’s stock in a transaction on Friday, September 25th. The stock was sold at an average price of $620.60, for a total transaction of $95,572.40. Following the transaction, the chief executive officer directly owned 389,302 shares in the company, valued at $241,600,821.20. This trade represents a 0.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Medpace Stock Up 1.0%

Medpace stock traded up $6.17 during mid-day trading on Tuesday, reaching $622.11. The company had a trading volume of 249,674 shares, compared to its average volume of 331,499. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The company has a 50 day moving average of $596.41 and a 200-day moving average of $517.30. The firm has a market cap of $17.36 billion, a price-to-earnings ratio of 36.47, a PEG ratio of 2.76 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Royal Bank Of Canada upped their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Jefferies Financial Group reissued a “hold” rating on shares of Medpace in a report on Monday, September 14th. Robert W. Baird boosted their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. BMO Capital Markets upped their target price on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Finally, Barclays set a $600.00 target price on Medpace in a research report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $595.20.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MEDP. American Capital Management Inc. acquired a new position in Medpace during the 2nd quarter worth $111,329,000. Focus Partners Advisor Solutions LLC bought a new position in Medpace in the 2nd quarter valued at $1,685,000. California State Teachers Retirement System increased its stake in shares of Medpace by 22.1% in the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock valued at $12,505,000 after buying an additional 4,719 shares during the period. BlackRock Inc. acquired a new stake in shares of Medpace in the 2nd quarter valued at $1,323,047,000. Finally, Madison Asset Management LLC bought a new stake in shares of Medpace during the second quarter worth $128,956,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.